
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Covigenix VAX-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Entos Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Aegis Completes Phase 1 Enrollment for COVID-19 Vaccine Booster Trial
Details : Covigenix VAX-002 is a plasmid DNA vaccine being evaluated in Phase 1/2 clinical trial studies to treat COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Covigenix VAX-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Entos Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $4.4 million
Deal Type : Financing
Aegis Life Receives Investment To Develop DNA-Encoded Antibodies Against Diseases
Details : Proceeds will support Aegis Life and Entos Pharmaceuticals' collaboration on DNA-based antibody therapeutics against HIV and malaria.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 19, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $4.4 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases
Details : The funding will be used to develop the Fusogenix PLV platform for the delivery of DNA-encoded monoclonal antibodies, including HIVV-102, directly inside the patient’s cells for the treatment of infectious diseases such as HIV, influenzas, and malaria.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
